Bristol-Myers Squibb Company ’s Second Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals, Inc. and Important Clinical Data in Immuno-Oncology
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2012 highlighted by the planned strategic acquisition of Amylin Pharmaceuticals and the presentation of important clinical data from the Company’s immuno-oncology pipeline. The Company also adjusted its GAAP EPS guidance range and confirmed its non-GAAP EPS guidance range for 2012.